AU2012363033B2 - Composition of novel carbohydrate drug for treatment of human diseases - Google Patents

Composition of novel carbohydrate drug for treatment of human diseases Download PDF

Info

Publication number
AU2012363033B2
AU2012363033B2 AU2012363033A AU2012363033A AU2012363033B2 AU 2012363033 B2 AU2012363033 B2 AU 2012363033B2 AU 2012363033 A AU2012363033 A AU 2012363033A AU 2012363033 A AU2012363033 A AU 2012363033A AU 2012363033 B2 AU2012363033 B2 AU 2012363033B2
Authority
AU
Australia
Prior art keywords
compound
fibrosis
cells
liver
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012363033A
Other languages
English (en)
Other versions
AU2012363033A1 (en
Inventor
Elena CHEKHOVA
Anatole A. Klyosov
Peter G. Traber
Eliezer Zomer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galectin Therapeutics Inc
Original Assignee
Galectin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Therapeutics Inc filed Critical Galectin Therapeutics Inc
Publication of AU2012363033A1 publication Critical patent/AU2012363033A1/en
Application granted granted Critical
Publication of AU2012363033B2 publication Critical patent/AU2012363033B2/en
Priority to AU2016222423A priority Critical patent/AU2016222423B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738—Cross-linked polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012363033A 2011-12-28 2012-09-14 Composition of novel carbohydrate drug for treatment of human diseases Active AU2012363033B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016222423A AU2016222423B2 (en) 2011-12-28 2016-09-01 Composition of novel carbohydrate drug for treatment of human diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161580830P 2011-12-28 2011-12-28
US61/580,830 2011-12-28
PCT/US2012/055311 WO2013101314A1 (en) 2011-12-28 2012-09-14 Composition of novel carbohydrate drug for treatment of human diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016222423A Division AU2016222423B2 (en) 2011-12-28 2016-09-01 Composition of novel carbohydrate drug for treatment of human diseases

Publications (2)

Publication Number Publication Date
AU2012363033A1 AU2012363033A1 (en) 2014-07-17
AU2012363033B2 true AU2012363033B2 (en) 2016-06-02

Family

ID=48698494

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012363033A Active AU2012363033B2 (en) 2011-12-28 2012-09-14 Composition of novel carbohydrate drug for treatment of human diseases
AU2016222423A Active AU2016222423B2 (en) 2011-12-28 2016-09-01 Composition of novel carbohydrate drug for treatment of human diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016222423A Active AU2016222423B2 (en) 2011-12-28 2016-09-01 Composition of novel carbohydrate drug for treatment of human diseases

Country Status (14)

Country Link
US (8) US8871925B2 (enExample)
EP (1) EP2797942B1 (enExample)
JP (3) JP6133894B2 (enExample)
KR (1) KR101968370B1 (enExample)
CN (1) CN104245717B (enExample)
AU (2) AU2012363033B2 (enExample)
BR (1) BR112014015940B1 (enExample)
CA (1) CA2861492C (enExample)
DK (1) DK2797942T3 (enExample)
ES (1) ES2699386T3 (enExample)
IL (1) IL233313A (enExample)
MX (1) MX363923B (enExample)
WO (1) WO2013101314A1 (enExample)
ZA (1) ZA201505849B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
JP6185473B2 (ja) * 2011-09-16 2017-08-23 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 非アルコール性脂肪性肝炎および非アルコール性脂肪肝疾患を処置するためのガラクト−ラムノガラクツロネート組成物
KR101968370B1 (ko) 2011-12-28 2019-04-11 갈렉틴 테라퓨틱스, 인크. 인간 질환의 치료를 위한 신규 탄수화물 약물의 조성물
ES2848538T3 (es) 2012-06-06 2021-08-10 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible
BR112015005772A2 (pt) 2012-09-17 2017-08-08 Galectin Therapeutics Inc método para a intensificação de imunoterapias específicas no tratamento de câncer
JP6055928B2 (ja) 2012-10-10 2016-12-27 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 糖尿病性腎症および関連障害の処置のためのガラクトース分枝炭水化物化合物
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
GB201502668D0 (en) * 2015-02-17 2015-04-01 Glycomar Ltd And Albert Bartlett & Sons Airdrie Ltd Method for isolation of polysaccharides
FR3036943A1 (fr) * 2015-06-02 2016-12-09 Echosens Dispositif non invasif de detection de lesion hepatique
MX394409B (es) * 2016-03-04 2025-03-24 Galectin Sciences Llc Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos.
EP3568139A4 (en) * 2017-01-13 2020-10-28 Sivanaray, Inc. COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR THE PREVENTION OR TREATMENT OF LIVER AND LIPID RELATED DISEASES
CA3062648A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
AR113011A1 (es) 2017-09-08 2020-01-15 Evelo Biosciences Inc Vesículas extracelulares bacterianas
JP2021529163A (ja) 2018-06-29 2021-10-28 グリコス バイオメディカル オーワイ コンジュゲート
DE102019003442A1 (de) 2019-05-15 2020-11-19 Ilma biochem GmbH Verwendung von niedermolekularen glykosidisch gebundenen endständigen Galactosiden und Fucosiden zur Bindung von als Galectin wirkenden Toxinen im Rahmen der Behandlung von Vergiftungen, insbesondere bei Vergiftungen mit Ricin
US20210100832A1 (en) * 2019-10-02 2021-04-08 Patchor Ltd. Injectable composition for the treatment of musculoskeletal disorders and methods of use thereof
WO2021123506A1 (en) 2019-12-18 2021-06-24 Glykos Biomedical Oy Stabile conjugate
EP4181910A4 (en) * 2020-07-17 2024-06-05 DSM Nutritional Products, LLC OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE
CN116211884B (zh) * 2023-02-16 2024-05-17 海孵(海南自贸区)医疗科技有限责任公司 一种鼻腔喷雾剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211653A1 (en) * 1998-05-13 2006-09-21 Yawei Ni Pharmaceutical compositions comprising Aloe pectins, and methods for their production and use
US20110046086A1 (en) * 2008-04-07 2011-02-24 Korea Institute Of Radiological & Medical Sciences Composition Comprising Polysaccharide Extracted from Panax Ginseng Preventing and Treating Liver Diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2132577A (en) 1934-08-28 1938-10-11 Gen Foods Corp Method of preparing pectin
US2444266A (en) 1944-03-31 1948-06-29 Us Agriculture Pectic materials and method of preparing same
US2503258A (en) 1948-01-23 1950-04-11 Us Agriculture Neutralization of pectinic acids with sodium bicarbonate
US4016351A (en) 1976-02-04 1977-04-05 Eschinasi Emile H Pectic substances with varying methoxyl content and process therefor
US4268533A (en) 1979-11-21 1981-05-19 General Foods Corporation Quick-set low methoxyl pectin composition
EP0181351A4 (en) * 1984-05-09 1989-06-21 Univ Australian METHOD FOR MODULATING IMMUNE REACTION.
US4686106A (en) 1986-06-16 1987-08-11 General Foods Corporation Pectin food product
US5071970A (en) 1988-11-23 1991-12-10 University Of Florida Process for producing pectin with a high-to-medium methoxyl content from beet pulp
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US7491708B1 (en) 1993-03-01 2009-02-17 David Platt Modified pectin
JP3360899B2 (ja) 1993-10-08 2003-01-07 日本医薬品工業株式会社 癌予防・治療剤
US5498702A (en) 1993-12-16 1996-03-12 California Natural Products Treated pectinic acid process and product
US5834442A (en) 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5681923A (en) 1995-10-06 1997-10-28 Platt; David Tumor derived carbohydrate binding protein
US6632797B2 (en) 1996-06-24 2003-10-14 Matti Siren Method of treating angiogenesis
KR100252194B1 (ko) 1997-10-10 2000-04-15 박호군 참당귀에서분리한신규한펙틴질다당류와그분리정제방법및그의면역증강제로서의용도
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
US6500807B1 (en) 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20030004132A1 (en) 2001-06-22 2003-01-02 Yan Chang Method and material for treating immune diseases
US20040121981A1 (en) 2001-11-21 2004-06-24 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US6890906B2 (en) 2001-11-21 2005-05-10 Glycogenesys, Inc. Method for controlling angiogenesis in animals
KR100594353B1 (ko) 2002-05-28 2006-07-03 주식회사 엠디바이오알파 신규한 인삼잎 및 줄기 다당체, 그 제조방법 및 그를활성성분으로 함유하는 항암제 및 항암보조제 조성물
JP2004107295A (ja) * 2002-09-20 2004-04-08 National Agriculture & Bio-Oriented Research Organization ヒスタミン遊離抑制剤
AU2004229399B2 (en) * 2003-04-07 2010-08-05 Prospect Therapeutics, Inc. Composition and uses of galectin antagonists
US20040223971A1 (en) 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
US20050008572A1 (en) 2003-04-29 2005-01-13 Ales Prokop Nanoparticular tumor targeting and therapy
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
CA2582428A1 (en) 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
ITFI20040174A1 (it) * 2004-08-03 2004-11-03 Protera S R L Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
US9646327B2 (en) 2011-08-09 2017-05-09 Yahoo! Inc. Disaggregation to isolate users for ad targeting
JP6185473B2 (ja) 2011-09-16 2017-08-23 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 非アルコール性脂肪性肝炎および非アルコール性脂肪肝疾患を処置するためのガラクト−ラムノガラクツロネート組成物
SG11201401330YA (en) * 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
KR101968370B1 (ko) 2011-12-28 2019-04-11 갈렉틴 테라퓨틱스, 인크. 인간 질환의 치료를 위한 신규 탄수화물 약물의 조성물
ES2848538T3 (es) 2012-06-06 2021-08-10 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible
BR112015005772A2 (pt) 2012-09-17 2017-08-08 Galectin Therapeutics Inc método para a intensificação de imunoterapias específicas no tratamento de câncer
JP6055928B2 (ja) 2012-10-10 2016-12-27 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 糖尿病性腎症および関連障害の処置のためのガラクトース分枝炭水化物化合物
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211653A1 (en) * 1998-05-13 2006-09-21 Yawei Ni Pharmaceutical compositions comprising Aloe pectins, and methods for their production and use
US20110046086A1 (en) * 2008-04-07 2011-02-24 Korea Institute Of Radiological & Medical Sciences Composition Comprising Polysaccharide Extracted from Panax Ginseng Preventing and Treating Liver Diseases

Also Published As

Publication number Publication date
CN104245717B (zh) 2017-10-24
JP6133894B2 (ja) 2017-05-24
US9649327B2 (en) 2017-05-16
EP2797942A4 (en) 2015-06-03
CN104245717A (zh) 2014-12-24
WO2013101314A1 (en) 2013-07-04
KR101968370B1 (ko) 2019-04-11
CA2861492C (en) 2019-09-24
US20230000898A1 (en) 2023-01-05
JP6262386B2 (ja) 2018-01-17
US8871925B2 (en) 2014-10-28
US20180256626A1 (en) 2018-09-13
AU2012363033A1 (en) 2014-07-17
IL233313A (en) 2017-08-31
US20170202870A1 (en) 2017-07-20
JP6415677B2 (ja) 2018-10-31
AU2016222423B2 (en) 2018-02-22
ES2699386T3 (es) 2019-02-11
US20210093656A1 (en) 2021-04-01
BR112014015940A8 (pt) 2021-09-28
JP2017149976A (ja) 2017-08-31
US20200078390A1 (en) 2020-03-12
US20140350238A1 (en) 2014-11-27
MX2014007934A (es) 2015-03-09
US8962824B2 (en) 2015-02-24
JP2018076519A (ja) 2018-05-17
BR112014015940B1 (pt) 2022-08-09
US10799525B2 (en) 2020-10-13
US9974802B2 (en) 2018-05-22
ZA201505849B (en) 2017-03-26
CA2861492A1 (en) 2013-07-04
MX363923B (es) 2019-04-08
US10420793B2 (en) 2019-09-24
US20130261078A1 (en) 2013-10-03
EP2797942A1 (en) 2014-11-05
US20150174151A1 (en) 2015-06-25
DK2797942T3 (en) 2018-12-10
US11413303B2 (en) 2022-08-16
BR112014015940A2 (pt) 2017-06-13
KR20140143137A (ko) 2014-12-15
AU2016222423A1 (en) 2016-09-22
EP2797942B1 (en) 2018-10-31
IL233313A0 (en) 2014-08-31
JP2015503658A (ja) 2015-02-02

Similar Documents

Publication Publication Date Title
US11413303B2 (en) Methods for treatment of arthritis
KR101974675B1 (ko) 비알콜성 지방간염 및 비알콜성 지방간 질환의 치료를 위한 갈락토-람노갈락투로네이트 조성물

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)